ADYX (Adynxx) Total Liabilities: $14.32 Mil (As of Sep. 2019)


ADYX Adynxx Inc ADYX
16 GF Score
Price $0.00
View Full Analysis

What is Adynxx Total Liabilities?

Adynxx ADYX -99.00% 16 Total Liabilities is $14.32 Mil as of Sep. 2019. GuruFocus rates ADYX with a GF Score™ of 16/100.

Adynxx's Total Liabilities for the quarter that ended in Sep. 2019 was $14.32 Mil.

Adynxx's quarterly Total Liabilities increased from Mar. 2019 ($2.74 Mil) to Jun. 2019 ($11.95 Mil) and increased from Jun. 2019 ($11.95 Mil) to Sep. 2019 ($14.32 Mil).

Adynxx's annual Total Liabilities declined from Dec. 2016 ($22.41 Mil) to Dec. 2017 ($17.27 Mil) and declined from Dec. 2017 ($17.27 Mil) to Dec. 2018 ($1.43 Mil).

Adynxx Total Liabilities Historical Data

* Premium members only.

The historical data trend for Adynxx's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adynxx Total Liabilities Chart

Adynxx Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.21 37.33 22.41 17.27 1.43

Adynxx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.15 1.43 2.74 11.95 14.32
ADYX
16GF Score
Adynxx Inc ADYX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adynxx Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Adynxx's Total Liabilities for the fiscal year that ended in Dec. 2018 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.376+(0+0.051
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.43

Total Liabilities=Total Assets (A: Dec. 2018 )-Total Equity (A: Dec. 2018 )
=9.679-8.252
=1.43

Adynxx's Total Liabilities for the quarter that ended in Sep. 2019 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.797+(0.519+1.1102230246252E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=14.32

Total Liabilities=Total Assets (Q: Sep. 2019 )-Total Equity (Q: Sep. 2019 )
=3.254--11.062
=14.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $14.32 Mil mean?
Adynxx (ADYX) has a Total Liabilities of $14.32 Mil as of Sep. 2019. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Adynxx and its competitors.
Is Adynxx's Total Liabilities too high?
Adynxx's current Total Liabilities is $14.32 Mil. Overall, Adynxx has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Adynxx's Total Liabilities compare to TRPX and MITI?
Adynxx's Total Liabilities of $14.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Adynxx and its competitors. Adynxx's current Total Liabilities is $14.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adynxx stock overvalued right now?
Adynxx (ADYX) has a current Total Liabilities of $14.32 Mil. The current Total Liabilities is $14.32 Mil. Adynxx's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Adynxx (ADYX), the current Total Liabilities is $14.32 Mil as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adynxx Business Description

Address 100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
16GF Score

Get the complete analysis for ADYX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price